SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-290388
Filing Date
2021-10-04
Accepted
2021-10-04 08:01:10
Documents
12
Period of Report
2021-10-02
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d175477d8k.htm   iXBRL 8-K 27056
  Complete submission text file 0001193125-21-290388.txt   149884

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atra-20211002.xsd EX-101.SCH 2891
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20211002_lab.xml EX-101.LAB 18138
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20211002_pre.xml EX-101.PRE 11407
5 EXTRACTED XBRL INSTANCE DOCUMENT d175477d8k_htm.xml XML 3376
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 211301056
SIC: 2836 Biological Products, (No Diagnostic Substances)